Trial record 1 of 1 for:    NCT01409135
Previous Study | Return to List | Next Study

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

This study is currently recruiting participants.
Verified March 2014 by Astellas Pharma Inc
Sponsor:
Collaborators:
Agensys, Inc.
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01409135
First received: July 29, 2011
Last updated: March 26, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)